Evidence map›Paper›PMID 41819567›Full record

ReviewJournal of obesity & metabolic syndrome2026

Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations.

Mi Kyung Kim, Eun Yeong Ha, Hye Soon Kim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of obesity & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mi Kyung KimDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0001-5750-3598
Eun Yeong HaDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0002-9534-4329
Hye Soon KimDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0001-6298-3506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising global prevalence of obesity and its associated health problems necessitate effective intervention strategies. Historically, many anti-obesity medications have been developed and later withdrawn because of unfavorable adverse event profiles. By contrast, recently introduced glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) demonstrate remarkable efficacy for weight loss. Furthermore, they confer beneficial effects on cardiovascular and renal outcomes and metabolic dysfunction-associated liver disease. Despite these benefits, adverse events such as retained gastric content and pulmonary aspiration remain a concern. Consequently, this review summarizes current evidence and offers clinical guidance on GLP-1 RA-related adverse effects.

Indexed as

Adverse reactionsDrug-related side effectsGlucagon-like peptide-1 receptor agonistsObesitySafety

Identifiers

PMID41819567
PMCPMC13158034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.